Indaptus Therapeutics, Inc. (INDP)
NASDAQ: INDP · Real-Time Price · USD
2.850
+0.640 (28.96%)
At close: Oct 15, 2026, 4:00 PM EDT
2.720
-0.130 (-4.56%)
After-hours: Oct 15, 2026, 7:56 PM EDT
Company Description
Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products.
Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors.
The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021.
Indaptus Therapeutics, Inc. is headquartered in New York, New York.
Indaptus Therapeutics, Inc.
| Country | United States |
| Founded | 2000 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 5 |
| CEO | Junyi Dai |
Contact Details
Address: Three Columbus Circle, 15th Floor New York, New York 10019 United States | |
| Phone | 646 427 2727 |
| Website | indaptusrx.com |
Stock Details
| Ticker Symbol | INDP |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 1857044 |
| CUSIP Number | 45339J204 |
| ISIN Number | US45339J2042 |
| Employer ID | 86-3158720 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Junyi Dai | Chief Executive Officer and Chairman |
| Yu Ding | Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 5, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Sep 30, 2026 | 8-K | Current Report |
| Sep 10, 2026 | 8-K | Current Report |
| Sep 8, 2026 | 8-K/A | [Amend] Current report |
| Sep 4, 2026 | 8-K | Current Report |
| Sep 4, 2026 | 424B5 | Filing |
| Sep 1, 2026 | 8-K | Current Report |
| Aug 31, 2026 | 424B5 | Filing |
| Aug 26, 2026 | 424B3 | Prospectus |
| Aug 25, 2026 | EFFECT | Notice of Effectiveness |